Breakthrough Seizures in Children Receiving Valproate Therapy.

Area of Science:

• Pediatric Neurology
• Clinical Pharmacology

Background:

• Breakthrough seizures in children with epilepsy on valproate therapy present a significant challenge.
• Limited data exists on the causes of these seizures and their relation to serum valproate levels in the Indian population.

Purpose of the Study:

• To investigate the clinical profile and serum valproate levels in children experiencing breakthrough seizures while on valproate treatment.
• To determine the association between clinical, demographic, and etiological factors and valproate levels in these patients.

Main Methods:

• A study involving 100 children (2-12 years) with epilepsy experiencing breakthrough seizures while on valproate therapy.
• Recording of clinical and demographic data, and estimation of serum valproate levels using an autoanalyzer.
• Phenytoin levels were also measured in a subset of patients on dual therapy.

Main Results:

• Valproate levels were subtherapeutic in 44%, therapeutic in 47%, and supratherapeutic in 9% of patients.
• No statistically significant association was found between valproate levels and age, sex, socioeconomic status, parental education, seizure type, or precipitating factors.
• Drug formulation and compliance did not significantly affect valproate levels.

Conclusions:

• Breakthrough seizures in children treated with valproate are not correlated with serum valproate levels.
• Clinical and demographic factors, drug formulation, and compliance do not appear to influence valproate levels in this context.